Conférences - Pharmacologie et développement des médicaments - États-Unis

Conference-Service.com met à la disposition de ses visiteurs des listes de conférences et réunions dans le domaine scientifique. Ces listes sont publiées pour le bénéfice des personnes qui cherchent une conférence, mais aussi, bien sûr, pour celui des organisateurs. Noter que, malgré tout le soin que nous apportons à la vérification des données entrées dans nos listes, nous ne pouvons accepter de responsabilité en ce qui concerne leur exactitude ou étendue. Pensez donc à vérifier les informations présentées avec les organisateurs de la conférence ou de la réunion avant de vous engager à y participer!

Les organisateurs peuvent soumettre une réunion ou une conférence pour inclusion dans nos listes, et ceci gratuitement.

1.
 
DDS USA 2016 — 3rd Annual Drug Discovery USA Congress 2016
ID
821675
Dates
03 oct 2016 - 04 oct 2016
Lieu
San Diego, États-Unis
Résumé
Oxford Global Conferences are proud to present the 3rd Annual Drug Discovery USA Congress, taking place on 3-4 October 2016 in San Diego, USA. Our Congress brings together a host of senior level experts to discuss recent developments in the industry and debate the best strategies and solutions to improve drug discovery going forward.
Contact
Guillaume Alonso;     Tél.: [1865248455];     Email.: g.alonso@oxfordglobal.co.uk
Sujets
Drug Discovery, medicinal chemistry, R&D, peptide drug discovery, strategies for target selection, genomic technologies, discovery research, novel stem cell assays, phenotypic screening strategies, primary cells, disease models, supporting innovation with informatics tools, new data analysis, integration platforms, ideas for efficient data exchange, gene editing.
2.
 
How to Prepare for an FDA Meeting — How to Prepare for an FDA Meeting
ID
829098
Dates
05 oct 2016 - 06 oct 2016
Lieu
Boston, États-Unis
Résumé
How to Prepare for an FDA Meeting

FDA meetings are undeniably one of the most important steps in the development of medicinal products. Whether you are developing a drug, biological product, medical device, generic, diagnostic or anything else regulated by the FDA, it is a good idea to get direct feedback from the FDA about their concerns regarding your product before embarking on expensive and time-consuming development steps. FDA meetings need to be included in all product development strategies. However, the best answers are the one obtained by asking the best questions. Not only the best questions but the conduct of the meeting, management of time, efficiency of response, careful consideration of the answers, all could lead to successful conclusion to the meeting. This workshop would discuss the what, who, when and how of the FDA meetings. Steps from requesting a meeting, preparing and submission of the information package, preparing for the meeting, the conduct of the meeting and follow-up will be discussed using real-life experience and case studies.

Despite a few guidance documents to help sponsors prepare for meetings with the FDA, it is a challenge to understand the most efficient and productive ways to strategize, prepare, conduct, and follow-up for these meetings. There are many misconceptions about the expectations from these meetings both for the sponsor and the FDA, and hence many sponsors fail to get the most benefit from them. Over the years, the FDA has also revised processes and practices for meeting with sponsors.

This two day seminar will provide valuable tips about the logistics, planning, conduct and best practices for all kinds of meetings with the FDA. Throughout the workshop, the author will discuss case studies and examples to highlight the common errors and potential solutions. This workshop contains a collection of practical tips from the instructor’s extensive FDA meeting experience. This one-of-a-kind workshop will provide step-by-step instructions and practical tips to the most productive meeting with FDA for all FDA-regulated organizations.

Learning Objective:

Understanding all kinds of FDA meetings for drugs, biologics, medical devices, and all FDA-regulated meetings

When to and not to do meetings with FDA

Creating, managing and defending rationale for meetings with FDA

Requesting process for FDA meetings

Creating a meeting information package and its regulatory requirements

Logistics of an FDA Meeting

Best practices for FDA meeting follow up

Who Will Benefit:

Regulatory affairs professionals

Senior management executives (CEO, COO, CFO, etc.)

Project managers

Clinical trial specialists

Regulatory compliance associates and managers

People investing in FDA-regulated product development projects

Contact
Peter Brown;     Tél.: [+1 410 501 5777];     Email.: pbrown@fdamap.com
3.
 
ComplianceOnline Pharma Summit 2016 – Risk Control and Compliance
ID
819554
Dates
06 oct 2016 - 07 oct 2016
Lieu
Philadelphia, États-Unis
Résumé
Pharmaceutical and biotechnology companies across the globe face unprecedented challenges in the dynamically changing clinical, regulatory and business landscape. Aging populations, chronic diseases, technology and treatment advances are expected to spur health sector growth in 2016. As we approach 2016, it is imperative that leaders in the pharma space understand the trends and shifts happening around them.Note: Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
Pharma Summit 2016 - Risk control & Compliance, Biopharma summit 2016, Pharma Conferences, Pharma Events, Biotech Pharma Conclave
4.
 
World ADC — World ADC San Diego
ID
803085
Dates
10 oct 2016 - 13 oct 2016
Lieu
San Diego, États-Unis
Résumé
Now in it’s 7th year, World ADC San Diego is the industry’s most definitive antibody drug conjugate forum. Its mission is to enable drug developers to realize the next generation of clinically successful ADC drugs. 
Contact
Jenny Barlow;     Tél.: [+1 212 537 5898];     Email.: info@hansonwade.com
Sujets
Develop Next Generation Clinically Transformative ADCs 2016 is set to be a momentous year for antibody-drug conjugates. Since the start of 2016 alone 3 new ADCs have entered human testing, joining the 54 ADCs already in clinical trials. The ADC industry is on the cusp of realizing the next therapeutic breakthrough. Rapidly diversifying payload, linker and antibody technologies and a surge of novel preclinical ADCs powering towards the clinic have all contributed to this gaining of momentum. Now in it’s 7th year, World ADC San Diego is the industry’s most definitive antibody drug conjugate forum. Its mission is to enable drug developers to realize the next generation of clinically successful ADC drugs. Covering the A-Z of ADCs, World ADC San Diego strikes the balance between distilling ground-breaking science with transformative research that will empower your programs tomorrow. This year, 650 prominent minds from 190 organisations will descend on World ADC San Diego giving you an unparalleled opportunity to foster new connections, catch-up with peers and progress business partnerships.
5.
 
Myths and Urban Legends in Drug Development: Lessons Learned for Small Biotech Companies
ID
839248
Date de début
11 oct 2016
Lieu
Cambridge, États-Unis
Résumé
Regis Technologies invites you for a seminar on "Myths and Urban Legends in Drug Development: Lessons Learned for Small Biotech Companies" delivered by guest speakers, Dr. Michelle Higgin and Dr. Lisa Lallos of PharmaDirections.
Contact
Kristine Biederer;     Tél.: [1-847-697-6000];     Email.: kbiederer@registech.com
Sujets
Biotechnology
Sujets apparentés
6.
 
Analytical Methods in Development and Manufacture of Drugs and Biologics: 2-Day In-Person Seminar by Ex-FDA Official
ID
834307
Dates
11 oct 2016 - 12 oct 2016
Lieu
San Francisco, États-Unis
Résumé
Analytical methods ensure quality of drugs and biologics. During last 2 decades, paradigm for quality of pharmaceutical products has shifted from ensuring quality by testing representative samples to building quality during manufacture of such products, leading to the concept of Quality by Design (QbD). This course starts with discussing the new paradigm of quality, QbD, and role of analytical methods in ensuring quality.Note: Use coupon code NB5SQH8N and get 10% off on registration.
Contact
Referral;     Tél.: [8887172436];     Email.: referral@complianceonline.com
Sujets
analytical methods development training, Quality by Design (QbD), verification, qualification, validation, bioassays, Good Manufacturing Practices (GMP)
7.
 
2nd Antibody Drug Conjugates Conference
ID
820020
Dates
24 oct 2016 - 25 oct 2016
Lieu
Boston, États-Unis
Résumé
We invite you to attend the 2nd Antibody Drug Conjugates Conference, which will take place October 24-25, 2016 in Boston, MA. This event will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and gain a fresh perspective on the emergence of recent data from ADC clinical trials, new linkers and payloads, personalized healthcare, site specific attachment, and ADC therapeutics. With the field of antibody drug conjugates rapidly expanding and the increasing number of ADC clinical trials, novel therapeutics are emerging. The ADC therapeutic area combines synthetic chemistry with rationale biology and is advancing monoclonal antibody treatments into the realm of precision medicine with improved effectiveness and therapeutic indices.
8.
 
ICBS2016-Madison — 5th Conference of the International Chemical Biology Society: Translational Chemical Biology
ID
829376
Dates
24 oct 2016 - 26 oct 2016
Lieu
Madison, WI, États-Unis
Résumé
Following successful meetings in Boston, Kyoto, San Francisco and Berlin, ICBS presents its Fifth Annual Conference: Translational Chemical Biology. Twenty-two confirmed invited speakers plus 22 registrants selected from submitted abstracts will present oral presentations in nine sessions including infectious disease, cancer, neurodegenerative disorders, regenerative medicine, imaging and biosensors, epigenetics, natural products, lipids, and the human microbiome. Two poster sessions will be held with evening receptions. ICBS will again recognize three early-stage scientists in a Rising Stars of Chemical Biology session. ICBS2016-Madison will create a vibrant forum for the exchange of information on the latest advances in chemical biology and progress toward translation of these findings in important therapeutic areas.
Contact
Laura Richards;     Tél.: [608-2656534];     Email.: icbs@union.wisc.edu
Sujets
chemical biology, drug discovery, imaging
9.
 
4th Antibody & Protein Therapeutics Conference
ID
820098
Dates
25 oct 2016 - 26 oct 2016
Lieu
Boston, États-Unis
Résumé
We welcome you to the 4th Antibody & Protein Therapeutics Conference, which will be held October 25-26, 2016 in Boston, MA. This conference strives to connect industry and academic researchers in the protein therapeutics field to facilitate discussion on the current state of the industry and discuss recent studies and challenges involved in therapeutic development.
10.
 
IMN — 8th Annual Immunogenicity and Bioassay Summit
ID
811218
Dates
26 oct 2016 - 28 oct 2016
Lieu
Baltimore, MD, États-Unis
Résumé
Following year-on-year success, CHI presents the Eighth Annual Immunogenicity and Bioassay Summit 2016: 3 conferences, FDA presenters plus 40+ additional presentations, 15+ interactive breakout round table and panel discussions, short courses, exhibit/poster hall, and networking opportunities with 250+ delegates. Immunogenicity Prediction & Control is designed to help investigators design and select non-immunogenic products for early-stage decision making, while Immunogenicity Assessment & Clinical Relevance and Optimizing Bioassays for Biologics will enable investigators to overcome the complexities of immunogenicity assessment and bioassays, and develop programs that ensure their products are safe and efficacious, and satisfy regulatory requirements.
Contact
Tél.: [781-972-5400];     Email.: chi@healthtech.com
Sujets
Immunogenicity, Clinical Relevance, Bioassays, Biologics
11.
 
FDA’s GMP Expectations for Phase I and First-in-Man Clinical Trials — FDA’s GMP Expectations for Phase I and First-in-Man Clinical Trials
ID
831616
Dates
27 oct 2016 - 28 oct 2016
Lieu
Boston, États-Unis
Résumé
Manufacturing an investigational product for the initial pilot clinical trials could pose a considerable logistical and financial challenge to developers. The first-in-man and pilot clinical trials are usually conducted in very small number of healthy participants with lower doses primarily to establish safety and hence do not need a significant amount of investigational material. The US FDA allows developers to test early stage investigational products under relaxed GMP requirements. The manufacturing requirements for early stage clinical trials are designed to assure adequate quality of the investigational product being tested without the excessive regulatory burden of full-scale GMP manufacturing. This workshop will present the current regulations, guidance documents and regulatory strategies available for manufacturing an early development stage product for Phase I and first-in-man clinical trials. Also discussed will be logistical issues with managing the supply of an early stage investigational product, and requirements for stability testing, storage and shipping, labeling, and documentations. Perspectives for different classes of products will be presented using case studies.
Contact
Peter Brown;     Tél.: [+1 410 501 5777];     Email.: pbrown@fdamap.com
Sujets
FDA GMP Regulations, Phase 1 Clinical trial, GMP Guidance Seminar, IND Submission, GMP for Medical Devices
12.
 
Pharma Congress 2016 — World Pharma Congress
ID
829030
Dates
07 nov 2016 - 09 nov 2016
Lieu
Las Vegas, États-Unis
Résumé
World Pharma Congress (Nov 07-09, 2016 Las Vegas, Nevada, USA) Organising Committee welcomes all Pharmaceutical experts around the globe. The conference series aims to provide a forum for worldwide researchers from various areas of Pharmacy, Medical, Health science and Life science by providing a platform for critical analysis of new data, and to share latest cutting-edge research findings and results about all aspects of Pharmaceutical Sciences.
Contact
Andrew Smith;     Tél.: [7025085200];     Email.: pharmacongress@pharmaceuticalconferences.com
Sujets
pharma conferences, pharma summits, pharma events, pharma meetings, pharmaceutical conferences usa, international pharma conferences, drug conferences, babe conferences, babe summit.
13.
 
Equivalence of Complex Drug Products: Scientific and Regulatory Challenges
ID
834766
Date de début
09 nov 2016
Lieu
New York, États-Unis
Résumé
The rise of bio- and nano-technologies has accelerated the development of complex drug products, a class of products that include—but are not limited to—Non Biological Complex Drugs (NBCDs). NBCDs (e.g., glatiramoids, iron-carbohydrate complexes, polymeric micelles, complex ocular emulsions, and liposomes) consist of different (closely related and often nanoparticulate) structures that cannot be fully quantitated and characterized by physico-chemical analytical means. The complex nature of NBCDs means that minute variations in the manufacturing process can substantially change the composition of final products, and this poses a challenge for the development of regulatory guidelines. While guidance for developing generic versions of small molecule drugs is well-established, and progress has been made for biologic complex drugs, there is very little guidance for follow-on versions of NBCDs. This is further complicated by the difficulty of aligning strategies of international regulatory bodies due to their different legal frameworks. To advance research and build consensus, it is necessary to engage together key stakeholders from academia, regulatory bodies, industry, and drug manufacturing.
Sujets
complex drugs, biosimilars, generics, biologics, drug discovery, drug development, regulation, nanotechnology, nano-technology, drug delivery, drug release
14.
 
4th Protein Expression, Purification & Characterization Conference
ID
825832
Dates
05 dec 2016 - 07 dec 2016
Lieu
Boston, États-Unis
Résumé
GTCbio is proud to present the 4th Protein Expression, Purification & Characterization Conference to be held on October 24-26, 2016 in Boston, MA. This meeting covers important topics including discussions on the expression of difficult proteins, new methods of purification, extended characterization of production cell lines, expression of difficult proteins, and new efficent analytical tools.
Contact
Kristen Starkey;     Tél.: [6262566405];     Email.: infogtcbio@gtcbio.com
Sujets
Protein Expression, Purification & Characterization
15.
 
BAC — 3rd Annual Re-Entering Antibacterial Discovery and Development Summit
ID
825053
Dates
07 dec 2016 - 09 dec 2016
Lieu
Boston, États-Unis
Résumé
By holding the Re-Entering Antibacterial Discovery and Development Summit, we at Cambridge Healthtech Institute are trying to contribute to the efforts to overcome the crisis of multidrug resistance, to revive the antibacterial pipeline, and to improve antimicrobial stewardship in the United States and worldwide. This Summit is designed as a forum for knowledge and opinion exchange among all stakeholders participating in discovery and development of new antibacterial agents. It includes several events listed below.
Contact
Pete DeOlympio;     Tél.: [781-972-5400];     Email.: chi@healthtech.com
Sujets
Compound validation, Preclinical development, Clinical phases, Regulatory concerns and pathways, Partnership seeking
16.
 
IMVACS — 11th Annual Immunization & Vaccine Summit
ID
825116
Dates
07 dec 2016 - 09 dec 2016
Lieu
Boston, États-Unis
Résumé
Globally, immunization has proven to be the gateway to health for millions, and continued investment in vaccine development provides a measureable return in reducing the burden of disease and safeguarding human development. Today, more than ever, vaccine technology remains at the forefront of the confrontation against infectious disease. Cambridge Healthtech Institute’s Eleventh Annual Immunization and Vaccine Summit will cover a range of topics in this evolving field, including the latest advancements and applications of vaccine technologies, development of effective vaccine adjuvants, and progress in DNA- and RNA-based vaccines.
Contact
Tél.: [781-972-5400];     Email.: chi@healthtech.com
Sujets
DNA- and RNA- Based Vaccines, Advances in Vaccine Technologies, Vaccine Adjuvants
Sujets apparentés
17.
 
Keystone Symposia: Biobetters and Next-Generation Biologics: Innovative Strategies for Optimally Effective Therapies
ID
830040
Dates
22 jan 2017 - 26 jan 2017
Lieu
Snowbird, Utah, États-Unis
Résumé
The purpose of this meeting is to examine different approaches for treatment of cancer and other diseases (e.g., fibrosis, autoimmunity and inflammatory diseases). The program will provide insights from academic and industry scientists on innovative biologics technologies and treatment strategies for ameliorating disease in an effort to identify synergies and opportunities to cross-fertilize approaches. Furthermore, the meeting includes perspectives from the US Food & Drug Administration and how the outlined strategies will impact the drug review and approval process. The intention is to better inform meeting attendees of current/future strategies for treating disease and best practices for transforming concepts into approved drugs.
Contact
Attendee Services;     Tél.: [970-262-1230 or 800-253-0685];     Email.: info@keystonesymposia.org
Sujets
Cancer, drug discovery, immunology
18.
 
Vaccines-2017 — International Conference on Vaccines-2017
ID
811250
Dates
20 fév 2017 - 22 fév 2017
Lieu
Baltimore, États-Unis
Résumé
This scientific conference will bring an opportunity to share potential benefits and limitations of vaccines in preventing and control of infectious and non-infectious diseases thereby enhancing the quality and longevity of life.Vaccines 2017 mainly showcases comprehensive approaches in Vaccines and research, virology. vaccine conference includes Plenary lectures, Keynote lectures and short courses by eminent personalities from around the world in addition to contributed papers both oral and poster presentations
Contact
James Martin;     Tél.: [1-302-231-6959];     Email.: Vaccines@madrige.com
Sujets
Vaccines, virology, Infectious and non infectious diseases, Therapeutic Medicines
Sujets apparentés
19.
 
Frontiers in Cancer Immunotherapy
ID
824381
Dates
27 fév 2017 - 28 fév 2017
Lieu
New York, NY, États-Unis
Résumé
This 2-day scientific symposium will explore emerging findings in basic science, translational research, and clinical studies to improve immunotherapeutic approaches in cancer treatment. The event will convene basic, preclinical, and clinical researchers active in the field of cancer immunotherapy, alongside industry representatives and government stakeholders. Dr. James Allison, Executive Director of the Immunotherapy Platform at the University of Texas MD Anderson Cancer Center and a pioneer in the field of cancer immunotherapy, will commence the conference with a Keynote Address. Plenary speakers will present on an array of topics, including: the evaluation of combination therapy strategies to improve clinical benefit; the development of immune-monitoring strategies for the identification of relevant prognostic and predictive biomarkers; the development of strategies to overcome immune tolerance; and the incorporation of genomics into immunotherapeutic research and clinical trials.
Sujets
Immunotherapy, Oncology, Immunology, Therapeutics, Clinical Trials, Vaccines, Diagnostics, Biomarkers, Genomics, Epigenomics, Epigenetics, Drug Discovery, Cancer
20.
 
Keystone Symposia - Kinases: Next-Generation Insights and Approaches
ID
825322
Dates
05 mar 2017 - 09 mar 2017
Lieu
Breckenridge, Colorado, États-Unis
Résumé
Decades of both basic and applied research have unequivocally established the importance the kinase family of phosphotransferase enzymes in virtually every aspect of organismal homeostasis. From the initial characterization of ATP-dependent phosphorylation in the liver by Gene Kennedy in 1954, our understanding of the family has grown from the diverse perspectives of enzymology, biochemistry, biophysics, structural biology, genetics, cellular biology, pharmacology and physiology. Importantly, these advancements have yielded transformative therapeutic approaches to disease, most notably in the field of cancer where kinase inhibition is helping to fulfill the promise of precision medicine. Yet even today, our perspectives on the complexity of this class of enzymes continues to evolve, and many of the most exciting advancements in the field are being made by applying modern-day insights and technological approaches to the diverse roles the enzymes can play in health and human disease. This meeting will be devoted to exploring this innovative leading edge of kinase research, and will bring together leading researchers from academic, clinical and pharmaceutical settings to explore and define the new horizons in the field of kinase biology.
Contact
Tél.: [1 800-253-0685];     Email.: info@keystonesymposia.org
Sujets
Kinases, Drug Discovery, Kinase Signaling, Kinase Inhibitor
21.
 
Keystone Symposia - Sex and Gender Factors Affecting Metabolic Homeostasis, Diabetes and Obesity
ID
825257
Dates
19 mar 2017 - 22 mar 2017
Lieu
Tahoe City, California, États-Unis
Résumé
There are fundamental aspects of metabolic homeostasis that are regulated differently in males and females, and influence both the development of diabetes and obesity and the response to pharmacological intervention. Still, most preclinical researchers avoid studying female rodents due to the added complexity of research plans. The consequence is the generation of data that risks being relevant to only half of the population. This is a timely moment to study sex differences in diseases as NIH leadership has asked scientists to consider sex as a biological variable in preclinical research, to ensure that women get the same benefit of medical research as men. The goal of this meeting is to fill a need in the scientific community by connecting interdisciplinary groups of scientists who normally would not have an opportunity to interact. This group includes investigators studying sex differences, the role of sex hormones, the systems biology of sex and the genetic contribution of sex chromosomes to metabolic homeostasis and diseases. Leaders of the pharmaceutical industry will present their views on sex-specific drug discovery. The meeting is expected to generate new knowledge and ideas on the importance of gender biology and medicine from a molecular standpoint to the population level, and to provide the methods to study them. It is intended to be a catalyst of a process that will lead to gender-specific treatments of metabolic diseases.
Contact
Tél.: [1 800-253-0685];     Email.: info@keystonesymposia.org
Sujets
sex, gender, metabolic homeostasis, diabetes, obesity, sex differences, estrogens, androgen, drug design, gender-specific medicine, metabolomics, genetics
Sujets apparentés
22.
 
8th Annual Biotherapeutics Analytical Summit
ID
829838
Dates
20 mar 2017 - 23 mar 2017
Lieu
Bethesda, États-Unis
Résumé
Today’s complex biologics formats and ever increasing regulatory demands necessitates that companies come up with the most efficient, accurate and robust analytical methods to characterize a molecule; find the most effective tools to assess the molecule’s physico-chemical properties to optimize its druggability and developability, and to ensure that the end product is consistently safe and efficacious when comparing between batches or between biosimilars and innovators. When it comes to batch-to-batch variation, as the saying goes, “process is the product” – process analytics and quality control are thus of biggest concern to manufacturers and regulators alike.
Contact
Bethany Gray;     Tél.: [781-972-5400];     Email.: chi@healthtech.com
23.
 
Keystone Symposia - HIV Vaccines
ID
825170
Dates
26 mar 2017 - 30 mar 2017
Lieu
Steamboat Springs, Colorado, États-Unis
Résumé
Despite great progress in preventing and treating HIV, new infections continue to plague communities around the world, and the need for an HIV vaccine is as urgent as ever. Several large cohorts of HIV-infected individuals have enabled tremendous advances over the past five years in understanding immune responses to natural HIV infection. These advances have included the isolation of broad and potent anti-HIV antibodies, defining their developmental pathways, the generation of native-like Env trimers for immunization, and high-resolution structures of the envelope glycoprotein in complex with bnAbs. By 2017, many of these discoveries will have enabled new concepts to transition into human clinical trials, including passive monoclonal antibody therapy and novel immunization approaches. These platforms, incorporating improved technology for monitoring immune responses, will drive major advances in the vaccine field. This HIV Vaccines meeting will present the latest results from human clinical studies, along with the cutting-edge basic science behind such trials to highlight approaches that may lead to an HIV vaccine, and also reveal the molecular underpinnings of B and T cell-mediated immunity.
Contact
Tél.: [1 800-253-0685];     Email.: info@keystonesymposia.org
Sujets
HIV Vaccines, HIV, natural infection, transmission biology, immunogen platforms, b-cells, t-cells,
Sujets apparentés
24.
 
Keystone Symposia - Modeling Viral Infections and Immunity
ID
825375
Dates
01 mai 2017 - 04 mai 2017
Lieu
Estes Park, Colorado, États-Unis
Résumé
Viral infection modeling has provided insights into the pathogenesis and treatment of HIV, HCV, HSV-2, CMV and other viruses. It has had impact in revealing the lifespan of infected cells, how rapidly virus is produced and cleared from the circulation, and the means for evaluating the effectiveness of antiviral treatments. HIV remains a global health threat and there is great interest in revealing features of the main HIV reservoir, latently infected cells and mechanisms of reducing the size of this reservoir by pharmacological means. Other important gaps in knowledge revolve around the cell-mediated and humoral immune responses to HIV, important for generating vaccines and broadly neutralizing antibodies as therapeutics, topics that will be discussed. Further, viral infections generally occur in tissues and thus the meeting will discuss imaging techniques and methods of modeling and analyzing spatial infection data, the role of tissue-resident memory cells, and important features of immune regulation, such as immune exhaustion, cytokine signaling between cells, and viral subversion of innate responses and escape from adaptive responses. The meeting will highlight what we believe are significant hurdles to curing viral infections and will bring together experimental virologists, physician scientists and modelers of various types and experience, groups that do not normally meet. It should foster new collaborations between experimentalists and theoreticians, and between theoreticians working on different viral infections or different aspects of viral infections, as well as help young scientists formulate new research directions and make connections with established senior scientists.
Contact
Tél.: [1 800-253-0685];     Email.: info@keystonesymposia.org
Sujets
modeling viral infections, immunity, viral infection, Modeling Immune Regulation, HIV, Modeling Cellular Immune Responses, Spatial Aspects of Infection
Sujets apparentés

États-Unis: liste de tous les évènements/conférences.

7th annual Biosimilars Europe conference
Superbugs & Superdrugs USA Conference & Exhibition

Bon à savoir...

Vous pouvez insérer un encadré afin de diffuser vos évènements et services dans cet espace.

Dernière mise à jour: 19 Septembre 2016